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ABSTRACT 
Background: The prevalence of beta-blocker eye drop prescribing and respiratory effect of ocular 
beta-blocker administration in people with asthma has been poorly quantified despite their 
potential for rapid systemic absorption. 
Methods: We measured the prevalence of ocular beta-blocker prescribing in people with asthma 
and ocular hypertension, and a nested case-control study (NCCS) measuring the risk of moderate 
exacerbations (rescue steroids in primary care) and severe exacerbations (asthma hospitalisation) 
using linked data from the UK Clinical Practice Research Datalink. We then performed a systematic 
review and meta-analysis of clinical trials evaluating changes in lung function following ocular beta-
blocker administration in people with asthma. 
Results: From 2000-2012, the prevalence of non-selective and selective beta-blocker eye drop 
prescribing in people with asthma and ocular hypertension fell from 23.0% to 13.4% and from 10.5% 
to 0.9% respectively. In the NCCS, the relative incidence (IRR) of moderate exacerbations 
significantly increased with acute non-selective beta-blocker eye drop exposure (IRR 4.83, 95%CI 
1.56-14.94) but not with chronic exposure. In the meta-analysis, acute non-selective beta-blocker 
eye drop exposure caused significant mean falls in FEV1 of -10.9% (95%CI -14.9 to -6.9), and falls in 
FEV1 of ≥20% affecting one in three. Corresponding values for selective beta-blockers in people 
sensitive to ocular non-selective beta-blockers was -6.3% (95%CI -11.7 to -0.8), and a non-significant 
increase in falls in FEV1 of ≥20%.  
Conclusion: Non-selective beta-blocker eye drops significantly affect lung function and increase 
asthma morbidity but are still frequently prescribed to people with asthma and ocular hypertension 
despite safer agents being available. 
 
 
 
 
What is already known on the subject 
Beta-blocker eye drops may be absorbed into the systemic circulation but the prevalence of beta-
blocker prescribing and impact on lung function and exacerbations in people with asthma has been 
poorly quantified. 
 
What this paper adds 
Acute non-selective beta-blocker eye drop exposure significantly affects lung function and increases 
asthma morbidity but are still frequently prescribed to people with asthma and ocular hypertension 
despite safer agents being available. 
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INTRODUCTION 
International guidelines recommend that beta-blockers are contraindicated in asthma over safety 
concerns regarding acute bronchoconstriction (1-3). This effect results from endogenous and 
exogenous catecholamine antagonism at the pulmonary beta2-adrenoceptor leading to unopposed 
cholinergic tone. However, beta-blockers are not uncommonly prescribed to people with asthma, in 
part because their risk has been poorly quantified. Although the respiratory effect of oral beta-
blockers in people with asthma appears to vary according to selectivity, dose and individual 
susceptibility, less is known regarding the effect of beta-blocker eye drops that may be systemically 
absorbed (4). 
 
Beta-blocker eye drops are effective therapy for managing ocular hypertension. They reduce 
aqueous humour production and intra-ocular pressure by antagonising ciliary body beta-
adrenoceptors thereby preventing complications such as visual loss (5). As with oral agents, beta-
blocker eye drops vary in their degree of beta1:beta2-adrenoceptor selectivity with betaxolol being 
the principal ocular selective beta-blocker in clinical use (6). Although applied topically, systemic 
absorption may occur via the nasolacrimal system or the conjunctiva, without undergoing first pass 
metabolism (7). Despite safety concerns, the respiratory effect of beta-blocker eye drops in asthma 
has been poorly quantified despite reports of asthma deaths associated with ocular administration 
(8). Oral beta-blockers have been reported to be prescribed to around 2.2% of adults with asthma 
annually but the prevalence of beta-blocker eye drop prescribing in people with asthma, and their 
subsequent effect on lung function and asthma morbidity remains uncertain (9). 
 
The aim of this study was to: measure beta-blocker eye drop prescribing in people with asthma and 
ocular hypertension; quantify the risk of asthma morbidity from ocular beta-blocker exposure; and 
meta-analyse clinical trial data evaluating changes in lung function following beta-blocker eye drop 
administration in people with asthma. 
METHOD 
Data source and population for pharmacoepidemiological studies 
Data were extracted from the UK Clinical Practice Research Datalink (CPRD) which contains 
electronic medical record (EMR) data from >5 million UK people (further details of the data source 
are contained in online supplement 1) (10-12). People with medically treated asthma and ocular 
hypertension were identified by Read Codes and prescriptions for asthma and ocular hypertension 
medicines. The cohort consisted of people ≥18 years present in CPRD between 01/01/2000 and 
31/12/2011. Subjects were eligible if they: were permanently registered with a general practice for 
≥1 year; were from HES linked practices; were defined by CPRD as being acceptable for use in 
research (meaning their data had met quality standards); had a Read Code for asthma and were 
issued one or more prescriptions for ocular hypertension medicines.  
 
Cohort entry was defined as the first ocular hypertension prescription issued on or after: 
01/01/2000; date of the first asthma medicine; date of the patient’s 18th birthday; and before the 
date of the patient’s 80th birthday. The cohort was followed until either of the following occurred: 
an asthma event (defined in the nested case control section below); deregistration from the general 
practice; one year following the last asthma medication (thereby censoring people with asthma that 
had resolved or was inactive); end of ocular hypertension medical treatment; or end of the study 
period (31/12/2011). Asthma medicines were defined as: inhaled short-acting beta2-agonists 
(SABA); inhaled corticosteroids (ICS); inhaled long-acting beta2-agonists (LABA); oral leukotriene 
antagonists; and oral methylxanthines (13). All patients were issued two or more prescriptions for 
asthma medication. Ocular hypertension medicines were defined as ocular: beta-blockers; carbonic 
anhydrase inhibitors; miotics; sympathomimetics; or prostaglandin analogues (14). End of ocular 
hypertension medical treatment was defined by the last prescription date for an ocular hypertension 
medicine (plus a 90 day grace period) when 180 days had passed without any subsequent 
prescription of an ocular antihypertensive. 
Drug utilisation study 
The quarterly prevalence of non-selective and selective beta-blocker eye drop prescribing was 
calculated between 01/01/2000 and 31/12/2011. The numerator consisted of the number of people 
issued ≥1 non-selective or selective beta-blocker eye drop prescription and the denominator the 
total number of people with active asthma and ocular hypertension in the cohort during the same 
quarter.  
 
Nested case control study 
Outcomes 
A population-based retrospective cohort using a matched, nested case-control design was used to 
account for time-varying confounders and drug exposure (15). Two nested case control studies were 
performed evaluating, 1) moderate asthma exacerbations and, 2) severe asthma exacerbations. 
Severe asthma exacerbations were defined as a hospitalisation for asthma (defined by ICD codes for 
asthma as the primary reason for hospitalisation). Moderate asthma exacerbations were defined by 
receipt of rescue oral steroids in primary care, identified as oral prednisolone prescriptions lasting 
less than 2 weeks in duration using ≥5mg strength tablets (therefore people taking maintenance 
corticosteroids were excluded from this analysis). For each outcome, the date of the first asthma 
event was the index date for case subjects. Please see online supplement 1 for further details. 
 
Controls 
Up to four controls were randomly selected from the same population and matched to each case on 
age decile, gender and calendar year of cohort entry using incidence density sampling. The risk set 
date was the index date for cases. Four cases of severe asthma exacerbation (3.1%) and 18 
moderate exacerbations (3.0%) were initially unmatched, but were later included matched on 
gender and calendar year of cohort entry only with sensitivity analysis performed excluding these 
cases.  
 Exposure 
Exposure was measured by the presence or absence of beta-blocker eye drop prescriptions issued 
prior to the index date. Beta-blocker eye drop exposure was categorised into: current acute 
exposure (defined as a prescription issued in a 30 day risk window before the index date and no 
previous prescriptions issued in days 31-365 before the index date); current chronic exposure 
(defined as a prescription issued in a 30 day risk window before the index date and ≥1 previous 
prescription issued in days 31-365 before the index date); and no exposure when there was no 
prescription issued in the risk window prior to the index date.  
 
Confounders 
The analyses were adjusted for the following confounders as described in online supplement 1 
namely: asthma medicines issued within 90 days of the index date (ICS; LABA; leukotriene 
antagonists; methylxanthines; oral steroids (for the severe asthma exacerbation analysis), and 
SABAs); ever hospitalised for asthma; respiratory tract infections (RTI); exact age; smoking status; 
body mass index (BMI); index of multiple deprivation; nasal polyps; Charlson comorbidity index; and 
attendance at a primary care asthma review within the previous year. Please see online supplement 
1 for further details. 
 
Nested case control study analysis 
Chi-squared tests and analysis of variance (ANOVA) were used to determine significant differences 
between patient characteristics. Multiple imputation was used to impute missing data on height, 
weight and smoking status as described in online supplement 1 (16).  Conditional logistic regression 
was used to compute odds ratios for the association between outcomes and ocular beta-blocker 
exposure. Using an incidence density sampling approach, odds ratios represented unbiased 
estimators of incidence rate ratios (IRR). Analysis was carried out using SPSS v21 and STATA v13. 
 Nested case control study sensitivity analyses 
For the nested case-control study, sensitivity analysis was performed: excluding people hospitalised 
within the risk period (assessing for potential immeasurable time bias); excluding people over the 
age of 40 years who smoked (assessing for potential misclassification with COPD where beta-
blockers may be better tolerated and risk underestimated); excluding cases not originally matched 
on age; adjusting for ICS categorised into high, moderate and low dose; adjusting for a history of 
animal, drug or food allergy; adjusting for other ocular antihypertensive use; using a 60 and 90 day 
risk window (to establish whether risk attenuated over time); and a complete case analysis. Finally, a 
self-controlled case series controlling for time-varying confounders was performed to further 
evaluate the risk of moderate asthma exacerbations with acute non-selective beta-blocker eye drop 
exposure to compare with the nested case-control study (17). Full details of the self-controlled case 
series approach are contained in the online supplement 2. 
 
Systematic review and meta-analysis 
A systematic review of MEDLINE, EMBASE and CENTRAL was conducted following standard Cochrane 
methodology identifying controlled clinical trials published through 1 May 2015 evaluating the 
respiratory effects of acute beta-blocker eye drop exposure in people with asthma. Data were 
independently extracted on: mean percentage change in FEV1 (reported as the mean difference, 
MD); number of people experiencing falls in FEV1 of ≥20% and respiratory symptoms (reported as 
the risk difference, RD). In studies which included mixed populations (asthma and COPD) only data 
for patients with asthma were included. For included studies, non-selective beta-blocker eye drops 
were evaluated in people with asthma never exposed to beta-blocker eye drops (with unknown 
clinical response), but selective beta-blocker eye drops (betaxolol) were only evaluated in people 
with asthma with demonstrated respiratory sensitivity to non-selective beta-blockers. A fixed-effect 
meta-analysis was undertaken in Review Manager (RevMan) v5.1 (Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2011). Sensitivity analyses and risk of bias was 
assessed as described in online supplement 3, which contains further details of the systematic 
review process including methodology for calculating missing standard deviations (18, 19).  
 
RESULTS 
Drug utilisation study 
The cohort consisted of 4865 people with active asthma and ocular hypertension (mean age 67.8 
years, 55.8% women) during which 128 severe asthma exacerbations and 598 moderate asthma 
exacerbations were identified. During follow-up, 1128 people (23.2%) were issued 36300 non-
selective beta-blocker eye drop prescriptions and 241 people (5.0%) were issued 5544 selective 
beta-blocker eye drop prescriptions. The quarterly prevalence of beta-blocker eye drop prescribing 
in adults with active asthma and ocular hypertension is presented in figure 1. The prevalence of non-
selective beta-blocker eye drop prescribing fell from a high of 23.0% (95% CI 20.0-26.3) in the first 
quarter of 2000 to 13.4% (95% CI 11.9-15.0) in the last quarter of 2011. The most commonly 
prescribed non-selective beta-blocker eye drops were timolol followed by levobunolol, then 
carteolol. The prevalence of betaxolol fell from 10.5% (95% CI 8.4-13.0) in the first quarter of 2000 to 
only 0.9% (95% CI 0.6-1.5) in the last quarter of 2011. 
 
Nested case control study 
Characteristics of cases and controls are shown in table 1. As expected, cases generally had 
significantly higher use of asthma medication, with a greater proportion having previously been 
hospitalised for asthma and experiencing a RTI in the 90 days prior to the index date. Crude and 
adjusted incidence rate ratios for the association between beta-blocker eye drop exposure and 
asthma exacerbations are presented in table 2. Acute non-selective beta-blocker eye drop exposure 
was associated with a 4.8-fold increased relative incidence of moderate asthma exacerbations (IRR 
4.83, 95%CI 1.56-14.94, P=0.006). Chronic beta-blocker eye drop exposure was not associated with a 
significantly increased risk of moderate or severe asthma exacerbations. Risk of severe asthma 
exacerbations from new non-selective beta-blocker eye drop exposure, and risk of both outcomes 
from new selective beta-blocker eye drop exposure could not be quantified because of a lack of 
exposure. Following multivariable adjustment, the strongest risk factors for moderate asthma 
exacerbations among people with asthma and ocular hypertension included: having had a RTI within 
the previous 90 days, having previously been hospitalised for asthma, the number of SABA 
prescriptions issued within the previous 90 days, BMI and smoking status (table 3). 
 
Sensitivity analyses and self-controlled case series 
Sensitivity analyses were in keeping with the main findings with an increased relative incidence of 
moderate asthma exacerbations associated with acute non-selective beta-blocker eye drop exposure 
(online supplement 1, supplementary tables 1 and 2). The relative incidence of moderate asthma 
exacerbations fell with increasing risk window duration in keeping with a short-lived risk following 
acute exposure. The self-controlled case series assessing acute non-selective beta-blocker eye drop 
exposure produced consistent findings with a 3.7-fold increased risk of moderate asthma 
exacerbations within the first 30 days of initiation (IRR 3.69 (95%CI 1.53-8.94), P=0.004) (please see 
online supplement 2 for further details). 
 
Systematic review and meta-analysis of clinical trials 
Of 203 references identified, nine controlled clinical trials evaluating single-dose beta-blocker eye 
drop exposure in people with asthma were included (online supplement 3: supplementary figure 1; 
supplementary table 4) (20-28). Non-selective beta-blocker eye drops were evaluated in 55 adults 
(mean age 47 years, 46% male) and selective beta-blocker eye drops in 33 adults (mean age 45 
years, 66% male). Timolol was the most commonly evaluated non-selective beta-blocker and 
betaxolol the only selective beta-blocker evaluated.  
 
Non-selective beta-blocker eye drops in unselected people with asthma 
Compared to control, acute non-selective beta-blocker eye drop exposure caused: a mean fall in 
FEV1 of -10.9% (95%CI -14.9 to -6.9; p<0.001) (figure 2); a significant increase in falls in FEV1 of ≥20% 
(risk difference 0.28, 95%CI 0.14 to 0.42; p<0.001) (online supplement 3: supplementary figure 2) 
with a number needed to harm of approximately one in three; and a non-significant increase in 
respiratory symptoms (risk difference 0.40, 95%CI -0.05 to 0.85; p=0.08).  
 
Selective beta-blocker eye drops in people with asthma with non-selective beta-blocker sensitivity 
Compared to control, acute selective beta-blocker eye drop exposure in people with asthma 
sensitive to non-selective beta-blocker eye drops caused: a mean fall in FEV1 from baseline of -6.3% 
(95%CI -11.7 to -0.8; p=0.03) (figure 2); a non-significant increase in falls in FEV1 of ≥20% (risk 
difference 0.17, 95%CI -0.05 to 0.40; p=0.70) (online supplement 3: supplementary figure 2); and a 
non-significant increase in respiratory symptoms (risk difference 0.27, 95% CI -0.06 to 0.61, p=0.11). 
 
Sensitivity analyses 
When FEV1 threshold was varied, non-selective beta-blocker eye drops caused a significant increase 
in falls in FEV1 of ≥15% (risk difference 0.34, 95%CI 0.19 to 0.49; p<0.001) equating to a number 
needed to harm of one in three (figure 3). Betaxolol eye drops in people with asthma sensitive to 
non-selective beta-blockers, caused a significant increase in falls in FEV1 of ≥15% (risk difference 
0.35, 95%CI 0.11 to 0.59; p=0.005) equating to a number needed to harm of one in three in people 
with prior sensitivity or a number needed to harm of one in nine people unselected on the basis of 
prior response (figure 3). The risk difference for falls in FEV1 of ≥15% for betaxolol 1% was 0.41 
(95%CI 0.15 to 0.67; p=0.002) compared to 0.15 (95%CI -0.22 to 0.53) for betaxolol 0.5%. Results 
from other sensitivity analyses were consistent with the main findings. 
 
 
Risk of bias 
No significant statistical heterogeneity was detected. Of the nine studies, five were non-randomised 
and two were unblinded at high risk of bias (online supplement 3: supplementary figure 3). No 
funnel plot asymmetry was found to suggest publication bias.  
 
 
DISCUSSION 
This study measured the prevalence of beta-blocker eye drop prescribing and the respiratory effect 
of beta-blocker eye drop exposure in people with asthma and ocular hypertension. Although beta-
blocker eye drop prescribing fell over the study period, 14% of people with asthma and ocular 
hypertension were still being prescribed a non-selective beta-blocker at the end of follow-up 
demonstrating a population at risk. Betaxolol prescribing also fell during the study period and now 
appears to be infrequently prescribed in the UK despite its potentially better safety profile perhaps 
related to the increased availability of compound eye drop preparations containing non-selective 
beta-blockers that may be preferentially prescribed to reduce treatment burden (14). 
 
The relative incidence of moderate asthma exacerbations was significantly increased within thirty 
days of new ocular non-selective beta-blocker use with similar results observed in the nested case-
control study and the self-controlled case series. In contrast, no significant increase in asthma 
morbidity was observed with chronic exposure in the nested case control study. The lack of effect 
with chronic exposure may be due to attenuation of risk from beta2-adrenoceptor up-regulation 
with chronic dosing (as suggested by studies evaluating chronic oral beta-blocker exposure in 
asthma) or possibly survival bias whereby longer-term treatment is more likely to occur in people 
tolerating acute exposure (29). Several readily identifiable risk factors significantly associated with 
increased asthma severity or transient airway hyperresponsiveness were identified for moderate 
exacerbations which clinicians could use to better judge risk from non-selective beta-blocker 
exposure. These included having had a recent or concomitant respiratory tract infection, a prior 
history of asthma hospitalisation, being a current smoker, increasing body mass index and SABA use. 
 
The meta-analysis of controlled clinical trials demonstrated that acute exposure to non-selective 
beta-blocker eye drops caused significant mean falls in FEV1 of 10.9%, falls in FEV1 of ≥20% affecting 
approximately one in three and a non-significant increase in respiratory symptoms. For mean falls in 
FEV1, findings were similar to the effects of oral non-selective beta-blockers in people with asthma 
(4). However, the number of people experiencing falls in FEV1 of ≥20% following oral beta-blocker 
administration was smaller suggesting that non-selective beta-blocker eye drops may carry a greater 
risk.  
 
Betaxolol administration in people sensitive to ocular non-selective beta-blockers caused only small 
significant mean falls in FEV1, and non-significant increases in falls in FEV1 of ≥20% and respiratory 
symptoms. However, smaller falls in FEV1 may still be clinically significant, and betaxolol caused 
significant falls in FEV1 of ≥15% with a number needed to harm equivalent to one in nine people 
with asthma unselected on the basis of prior response. Falls in FEV1 ≥15% following acute betaxolol 
exposure appeared to be significant for betaxolol 1% compared to betaxolol 0.5% suggesting a 
possible dose response relationship which has also be demonstrated with acute oral selective beta-
blocker exposure (4).   
 
The most commonly evaluated non-selective beta-blocker eye drop in our cohort was timolol which 
has greater selectivity for the beta2-adrenoceptor than other commonly used non-selective beta-
blockers. In this regard, the absolute degree of beta2-adrenoceptor binding affinity (i.e. the 
equilibrium dissociation constant, Kd) shows a rank order of 
timolol>carvedilol>propranolol>nadolol>sotalol, potentially explaining the apparent greater risk 
following ocular administration potentiated by the lack of first pass liver metabolism and rapid 
systemic absorption. This rapid systemic absorption has been compared to that of systemic exposure 
following intravenous beta-blocker administration in terms of beta2-adrenoceptor occupancy and 
cardiopulmonary effects (7). It is uncertain whether any patients in our cohort routinely performed 
lacrimal duct compression following beta-blocker eye drop administration which could potentially 
modify the risk of systemic absorption and therefore risk of exacerbation. Despite this, our findings 
suggest that acute non-selective beta-blocker eye drops cause significant changes in lung function in 
people with asthma and also increase asthma morbidity in the real world.  
 
Strengths and limitations 
A key strength of our study is that it combines pharmacoepidemiological analysis of linked routine 
health data supported by meta-analysis of clinical trial data, making it the most comprehensive 
evaluation on the risks of beta-blocker eye drops in people with asthma. However, our study has 
several limitations. First, it was not possible to comprehensively evaluate all types of ocular beta-
blocker exposure in our nested case control study due to limited available data. Residual 
confounding from unmeasured covariates may also exist because data on lung function was not 
routinely available. However the self-controlled case series is a design in which the person acts as 
their own control and this produced consistent findings for acute non-selective beta-blocker 
exposure.  
 
Exposure to oral steroids may conceivably induce or worsen ocular hypertension acting as a 
potential confounder by theoretically increasing the likelihood of treatment with beta-blocker eye 
drops. However, this is unlikely to have influenced our results for several reasons. First, the 
increased risk with non-selective beta-blocker eye drops was seen with moderate exacerbations 
were the outcome of interest consisted of incident rescue oral steroid use. Second, the distribution 
of ocular hypertensive medication use among cases and controls is similar suggesting no significant 
difference in the severity of ocular hypertension between groups. Lastly, sensitivity analysis 
additionally adjusting for ocular antihypertensive use produced consistent results. 
 
The nested case control study outcomes relied upon accurate electronic prescribing and discharge 
coding and potentially not all outcomes were identified. Nevertheless, hospital discharges are 
routinely recorded in the UK and almost all chronic community prescriptions are issued 
electronically from general practice, including most drugs recommended by specialists. Limitations 
of our meta-analysis include the small number of participants, the potential risk of bias from non-
randomised or unblinded studies and the use of FEV1 which may be less sensitive than other 
methods at measuring airway resistance such as impulse oscillometry (31). Despite these limitations, 
results were generally consistent between study designs and were similar to a previous meta-
analysis evaluating oral beta-blockers in asthma (4). 
 
In conclusion, initiating treatment with non-selective beta-blocker eye drops causes significant 
changes in lung function in people with asthma and ocular hypertension, and is associated with 
increased asthma morbidity in the real world. Nevertheless, people with asthma and ocular 
hypertension are still frequently prescribed non-selective beta-blocker eye drops whilst safer 
selective agents are infrequently prescribed. These findings support recommendations that non-
selective beta-blocker eye drops should be avoided in people with asthma and ocular hypertension. 
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Table 1. Characteristics of cases and controls in the nested case control study. 
 
 
Characteristics 
Severe exacerbation 
Number (%) 
Moderate exacerbation 
Number (%) 
Cases 
N=128 
Controls 
N=489 
Cases 
N=598 
Controls 
N=2196 
Age (years, SD) ¥ 70.0 (12.3) 73.0 (9.6) 70.3 (10.5)* 71.6 (8.9) 
Female gender 85 (66.4) 328 (67.1) 85 (66.4) 328 (67.1) 
Years of follow-up (SD) ¥ 2.4 (2.6) 2.4 (2.6) 1.6 (2.2) 1.5 (2.1) 
Asthma therapy      
-ICS 57 (44.5) 235 (48.1) 266 (44.5) 1022 (46.5) 
-LABA 36 (28.1)* 66 (13.5) 72 (12.0) 213 (9.7) 
-LABAICS 43 (33.6) 141 (28.8) 185 (30.9)* 560 (25.5) 
-Leukotriene antagonist 15 (11.7) 22 (4.5) 23 (3.8)* 28 (1.3) 
-Methylxanthine  24 (18.8) 51 (10.4) 28 (4.7) 90 (4.1) 
-Oral steroid 72 (56.3)* 84 (17.2) n/a n/a 
-No. of SABA prescriptions (SD) ¥ 3.0 (2.5)* 1.7 (1.6) 1.6 (1.6)* 1.2 (1.4) 
Ocular hypertension therapy     
  -Non-selective beta-blocker 15 (11.7) 75 (15.3) 84 (14.0) 303 (13.8) 
  -Selective beta-blocker 5 (3.9) 10 (2.0) 15 (2.5) 77 (3.5) 
  -Prostaglandin analogue 84 (65.6) 349 (71.4) 441 (73.7) 1598 (72.8) 
  -Carbonic anhydrase inhibitor 45 (35.2) 131 (26.8) 161 (26.9) 618 (28.1) 
  -Sympathomimetic 12 (16.4) 67 (13.7) 48 (8.0) 207 (9.4) 
  -Miotic 5 (3.9) 20 (4.1) 34 (5.7) 89 (4.1) 
Comorbidity     
-Nasal polyps  9 (7.0) 24 (4.9) 23 (3.8) 99 (4.5) 
-BMI (SD) ¥ 27.4 (5.7) 27.3 (5.3) 28.2 (5.4)* 27.4 (6.1) 
-Charlson comorbidity index (SD) ¥ 2.7 (2.0) 2.5 (1.9) 2.4 (1.8) 2.5 (1.9) 
Smoking status     
-Current smoker 13 (10.2) 82 (16.8) 100 (16.7)* 229 (10.4) 
-Ex-smoker 66 (51.6) 258 (52.8) 310 (51.8) 1131 (51.5) 
-Non-smoker 39 (30.5) 129 (26.4) 169 (28.3) 709 (32.3) 
-Missing 10 (7.8) 20 (4.1) 19 (3.2) 127 (5.8) 
Primary care asthma review 51 (39.8) 151 (30.9) 253 (42.3) 882 (40.2) 
Previous asthma hospitalisation 32 (25.0)* 20 (4.1) 30 (5.0)* 47 (2.1) 
RTI 90 days prior to index date 29 (22.7)* 50 (10.2) 89 (14.9)* 129 (5.9) 
 ¥Continuous variables analysed with ANOVA, otherwise categorical variable analysed using Chi-square test.  
*Characteristics with statistically significant differences between cases and controls (p-value < 0.05). 
SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-agonist, LABAICS = long-acting 
beta2-agonist in combination inhaler with ICS, SABA = short-acting beta2-agonist, RTI = respiratory tract 
infection, BMI = Body mass index. Severe exacerbation = asthma hospitalisation. Moderate 
exacerbation = receipt of rescue oral steroid in primary care.
Table 2. Crude and adjusted incidence rate ratios (IRR) for the association between beta-blocker eye drop exposure and asthma exacerbations in the 
nested case control study. 
Severe exacerbation = asthma hospitalisation. Moderate exacerbation = receipt of rescue oral steroid in primary care.  
Empty cells = unable to estimate due to lack of exposure in the risk window.  
 
 
 
 
 
 
 Any exposure Acute exposure Chronic exposure 
 Crude Adjusted Crude Adjusted Crude Adjusted 
 IRR IRR 95% CI p-value IRR IRR 95% CI p-value IRR IRR 95% CI p-value 
Non-selective beta-blocker             
 Severe exacerbation 0.97 1.08 0.48-2.42 0.860 - - - - 1.04 1.10 0.49-2.49 0.818 
 Moderate exacerbation 1.16 1.21 0.89-1.66 0.224 4.01 4.83 1.56-14.94 0.006 1.06 1.11 0.81-1.54 0.517 
Selective beta-blocker             
 Severe exacerbation 1.85 1.85 0.32-10.88 0.496 - - - - 1.85 1.85 0.32-10.89 0.494 
 Moderate exacerbation 0.85 0.98 0.47-2.02 0.945 - - - - 0.85 0.97 0.47-2.01 0.941 
Table 3. Characteristics associated with risk of moderate asthma exacerbations among people with 
asthma and ocular hypertension. 
 
Characteristic 
Primary care asthma exacerbation 
Crude IRR (95%CI) Adjusted IRR (95%CI) p-value 
RTI within the last 90 days 2.85 (2.12-3.82) 2.93 (2.14-4.00) 0.001 
Past asthma hospitalisation 2.93 (1.81-4.70) 2.10 (1.25-3.53) 0.001 
Smoker 1.86 (1.37-2.54) 1.72 (1.22-2.42) 0.002 
SABA prescription* 1.20 (1.13-1.28) 1.17 (1.10-1.25) 0.001 
BMI¥ 1.02 (1.01-1.04) 1.03 (1.01-1.05) 0.002 
 
* Per additional SABA prescription in the previous 90 days (continuous variable).  
¥ Per unit increase in BMI (continuous variable). Other variables are categorical variables. 
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Figure 1. Prevalence of beta-blocker eye drop prescribing among people with active asthma and 
ocular hypertension. 
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Figure 2: Mean change in FEV1 following acute beta-blocker eye drop exposure. 
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Figure 3: Falls in FEV1 of 15% or greater following acute beta-blocker eye drop exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
ONLINE SUPPLEMENT 1: BETA-BLOCKER EYE DROPS IN ASTHMA 
 
PHARMACOEPIDEMIOLOGYICAL STUDY SUPPLEMENTARY METHODS 
 
Further details on data source 
The UK Clinical Practice Research Datalink (CPRD) contains linked health data about patient 
demographics, prescriptions, diagnoses, hospitalizations and deaths. Diagnoses within CPRD are 
recorded using Read Codes, a hierarchical thesaurus of coded clinical terms used in UK primary care 
(10). Approximately 60% of general practices in CPRD are linked to the Hospital Episode Statistics 
(HES) database, containing details of admissions to NHS hospitals in England. HES diagnoses are 
recorded using the International Classification of Disease (ICD10) coding system. General practices 
and patients within CPRD are required to meet defined quality standards in order to contribute data. 
Diagnoses within CPRD have high validity with a positive predictive value for respiratory disease and 
glaucoma of around 90% (11, 12). The study was approved by the Independent Scientific Advisory 
Committee for Medicines and Healthcare products Regulatory Agency database research (and is part 
of protocol 12_061R3). The observational studies are reported according to STROBE (Strengthening 
the Reporting of Observational Studies in Epidemiology) requirements. 
 
Further details on population and outcomes used in the nested case control analysis 
The study population was restricted to people with asthma and ocular hypertension so that controls 
were sampled from a more representative population. Severe exacerbations were defined as a 
hospitalisation for asthma identified by the following ICD codes: J45.0, J45.1, J45.8, J45.9, J46, 493, 
493.0, 493.1, 493.9. Moderate exacerbations were defined by receipt of rescue oral steroids defined 
as oral prednisolone prescriptions lasting less than 2 weeks in duration using ≥5mg strength tablets. 
People with non-rescue oral steroids were excluded from the moderate exacerbation analysis to 
prevent outcome misclassification bias. Asthma death was not evaluated as an outcome due to lack 
of power. 
Further details on confounders assessed in the nested case control analysis 
To account for differences in asthma severity, prescriptions issued within 90 days of the index date 
were modelled as categorical exposure indicators (ICS, LABA, leukotriene antagonists, 
methylxanthines, oral steroids) and as continuous exposure indicators (total number of SABA 
prescriptions issued within 90 days of the index date). Additional risk adjustment was performed for: 
ever hospitalised for asthma; respiratory tract infection (RTI) within 90 days of the index date; nasal 
polyps; attendance at a primary care asthma review within the previous year (categorical variables); 
smoking status (categorised into current, ex-smoker, never smoked); exact age; body mass index 
(BMI); index of multiple deprivation; Charlson comorbidity index (continuous variables).  
 
Sensitivity analysis was performed evaluating the effect of adjusting for ICS dose within the risk 
window. All doses of ICS were converted to fluticasone-equivalent doses based on their relative 
topical potency (1). Dose equivalencies used were beclomethasone 100 μg, budesonide 100 μg, 
fluticasone 50 μg, clenil 100 μg, ciclesonide 50 μg, mometasone 50 μg. The converted doses were 
categorised as high (fluticasone ≥1000 μg/day), moderate (500–999 μg/day) and low (< 500 μg/day). 
Sensitivity analysis was also performed modelling a history of animal, drug or food allergy recorded 
in the primary care medical record before the index date. 
 
Further details on multiple imputation used in the nested case control analysis 
Multiple imputation was used to impute missing data on height, weight and smoking status 
assuming data was missing at random. The imputation model included all variables relating to 
clinical characteristics, asthma events, asthma medication and beta-blocker eye drop exposure. 
Multiple imputation was carried out using fully conditional specification, with linear regression for 
continuous variables and logistic regression for categorical variables using five cycles analysed using 
Rubin’s rules (16). 
 
PHARMACOEPIDEMIOLOGYICAL STUDY SUPPLEMENTARY RESULTS 
Supplementary table 1. Sensitivity analyses for non-selective beta-blocker eye drop use and 
asthma events. 
Sensitivity analyses excluding patients: hospitalised within the risk window; smokers >40 years of age; cases unmatched on 
age; and a complete case analysis; varying risk window duration. IRR=incidence rate ratio. Adjusted results presented. 
Severe exacerbations = asthma hospitalisation. Moderate exacerbation = receipt of rescue oral steroids in primary care. 
Other ocular hypertensives = carbonic anhydrase inhibitors, prostaglandin analogues, miotics and sympathomimetics. 
 
 
 
 
 
 
 Any exposure Incident exposure Prevalent exposure 
 IRR 95% CI IRR 95% CI IRR 95% CI 
Adjusting for other ocular hypertensives       
 Severe exacerbation 0.96 0.42-2.23 - - 0.98 0.42-2.28 
 Moderate exacerbation 1.26 0.92-1.73 5.08 1.65-15.70 1.14 0.82-1.59 
ICS modelled by dose       
 Severe exacerbation 0.87 0.39-1.94 - - 0.89 0.40-1.97 
 Moderate exacerbation 1.24 0.90-1.69 4.78 1.54-14.83 1.13 0.81-1.56 
Adjusted for allergies       
 Severe exacerbation 0.97 0.44-2.14 - - 0.99 0.45-2.18 
 Moderate exacerbation 1.21 0.89-1.65 4.82 1.55-14.97 1.10 0.80-1.52 
Hospitalised in risk window       
 Severe exacerbation 1.22 0.52-2.87 - - 1.26 0.53-2.97 
 Moderate exacerbation 1.24 0.89-1.72 4.55 1.46-14.13 1.12 0.79-1.57 
Smokers over 40 years       
 Severe exacerbation 0.88 0.35-2.18 - - 0.90 0.36-2.23 
 Moderate exacerbation 1.13 0.79-1.60 3.98 1.12-14.11 1.04 0.72-1.49 
Unmatched on age       
 Severe exacerbation 1.09 0.48-2.45 - - 1.11 0.49-2.50 
 Moderate exacerbation 1.18 0.86-1.62 4.81 1.56-14.79 1.07 0.77-1.49 
Complete case analysis       
 Severe exacerbation 1.25 0.52-3.02 - - 1.29 0.53-3.12 
 Moderate exacerbation 1.19 0.85-1.65 7.77 2.23-27.09 1.06 0.75-1.49 
60 days risk window       
 Severe exacerbation 0.81 0.38-1.71 - - 0.85 0.40-1.80 
 Moderate exacerbation 1.12 0.84-1.49 1.96 0.85-4.75 1.06 0.79-1.43 
90 day risk window       
 Severe exacerbation 1.00 0.49-2.02 - - 1.08 0.53-11.56 
 Moderate exacerbation 1.10 0.83-1.45 1.61 0.74-3.50 1.05 0.78-1.40 
Supplementary table 2. Sensitivity analyses for selective beta-blocker eye drop use and asthma 
events. 
Sensitivity analyses excluding patients: hospitalised within the risk window; smokers >40 years of age; cases unmatched on 
age; and a complete case analysis; varying risk window duration. IRR=incidence rate ratio. Adjusted results presented. 
Severe exacerbations = asthma hospitalisation. Moderate exacerbation = receipt of rescue oral steroids in primary care. 
Other ocular hypertensives = carbonic anhydrase inhibitors, prostaglandin analogues, miotics and sympathomimetics. 
 
 
 
 
 
 
 
 
 Any exposure Incident exposure Prevalent exposure 
 IRR 95% CI IRR 95% CI IRR 95% CI 
Adjusting for other ocular hypertensives       
 Severe exacerbation 1.59 0.26-9.70 - - 1.59 0.26-9.70 
 Moderate exacerbation 0.99 0.47-2.05 - - 0.97 0.47-2.02 
ICS by dose       
 Severe exacerbation 1.30 0.25-6.77 - - 1.31 0.25-6.76 
 Moderate exacerbation 0.96 0.47-2.00 - - 0.96 0.46-1.98 
Adjusted for allergies       
 Severe exacerbation 1.46 0.30-7.12 - - 1.47 0.30-7.12 
 Moderate exacerbation 0.98 0.48-2.03 - - 0.98 0.47-2.02 
Hospitalised in risk window       
 Severe exacerbation 1.66 0.27-10.21 - - 1.67 0.27-10.21 
 Moderate exacerbation 1.03 0.50-2.14 - - 1.02 0.49-2.13 
Smokers over 40 years       
 Severe exacerbation 0.89 0.09-8.55 - - 0.89 0.09-8.57 
 Moderate exacerbation 0.94 0.38-2.36 - - 0.94 0.38-2.36 
Unmatched on age       
 Severe exacerbation 1.94 0.33-11.55 - - 1.94 0.33-11.53 
 Moderate exacerbation 0.99 0.48-2.06 - - 0.98 0.47-2.04 
Complete case analysis       
 Severe exacerbation 2.64 0.33-21.23 - - 2.63 0.33-21.11 
 Moderate exacerbation 0.98 0.46-2.08 - - 0.98 0.46-2.08 
60 day risk window       
 Severe exacerbation 1.87 0.32-11.07 - - 1.88 0.32-11.10 
 Moderate exacerbation 0.82 0.45-1.51 - - 0.85 0.46-1.57 
90 day risk window       
 Severe exacerbation 2.88 0.72-11.56 - - 2.87 0.71-11.56 
 Moderate exacerbation 0.81 0.45-1.47 - - 0.86 0.47-1.55 
ONLINE SUPPLEMENT 2: BETA-BLOCKERS EYE DROPS IN ASTHMA 
 
SELF-CONTROLLED CASE SERIES SUPPLEMENTARY METHOD 
 
Self-controlled case series study and risk periods 
A secondary analysis evaluating risk of moderate exacerbations with acute non-selective beta-
blocker eye drop exposure was performed using a case-exposure self-controlled case series (SCCS). 
For this analysis a 360 day observation period was used commencing 180 days prior to incident non-
selective beta-blocker eye drop prescription (defined as the first prescription in people with at least 
1 year’s follow-up prior to receipt). A 30 day pre-risk period was excluded from the analysis to 
account for event-dependent exposures (17). Oral steroid prescriptions issued within eight days of 
each other were considered the same moderate exacerbation event. A 30 day acute risk period 
commencing from the date of the incident prescription was used to allow comparison with the 
nested case control study. Exposure beyond the 30 day acute risk period was defined as chronic 
exposure. End of exposure was determined as 30 days following the date of the last non-selective 
beta-blocker eye drop prescription.  
 
Self-controlled case series confounder adjustment and data analysis 
The SCCS controls for time-fixed confounding. To control for time-varying confounding, the 
observation period was restricted to 360 days and adjustment made for the following time-varying 
exposures: ICS; LABAs; leukotriene antagonists; methlyxanthines; total number of SABA 
prescriptions; and seasonal variation. Age was not a significant time-varying confounder in this 
analysis because of the short study period. The duration of any hospitalizations occurring during the 
study period were calculated and this person time subtracted from each corresponding exposure 
group to prevent immeasurable time bias. The SCCS was analysed using conditional Poisson 
regression producing IRRs and 95% confidence intervals (17). 
 
SELF-CONTROLLED CASE SERIES SUPPLEMENTARY RESULTS 
 
The risk of moderate asthma exacerbations with acute beta-blocker eye drop exposure was 
evaluated in 26 eligible people (mean age 66 years, 53.8% women) initiating non-selective beta-
blocker eye drops who experienced 48 moderate exacerbations during the observation period 
(supplementary table 3). Non-selective beta-blocker eye drops were associated with a 3.7-fold 
increased risk of moderate asthma exacerbation within the first 30 days of initiation (IRR 3.69, 95%CI 
1.53-8.94, P=0.004).  
 
 
Supplementary table 3. Incidence rate ratios for non-selective beta-blocker eye drop exposure and 
moderate asthma exacerbations in the self-controlled case series. 
 
  
  IRR = incidence rate ratios for a 30 day acute risk period. 
 
 
 
 
 
 
 
 
 
 
 
 
Risk  
Period 
Person time 
(Days) 
Events Crude  
IRR 
Adjusted 
IRR 
Adjusted 
95%CI 
 
p-value 
Baseline 4724 18 1.00 Reference - - 
Pre-risk 769 2 0.66 0.67 0.15-2.97 0.596 
Acute 766 11 3.63 3.69 1.53-8.94 0.004 
Chronic 3030 17 1.38 1.24 0.52-2.94 0.630 
ONLINE SUPPLEMENT 3: BETA-BLOCKER EYE DROPS IN ASTHMA 
 
SYSTEMATIC REVIEW AND META-ANALYSIS SUPPLEMENTARY METHODS 
 
A systematic review of MEDLINE, EMBASE and CENTRAL databases was conducted following 
standard Cochrane methodology using a pre-specified protocol and search strategy to identify all 
controlled clinical trials published through 1 May 2015 evaluating the respiratory effects of acute 
beta-blocker eye drop exposure in people with asthma. Study selection was performed 
independently by two reviewers (DM and TD). Full texts were obtained for articles considered of 
relevance, and independently appraised by the reviewers with inclusion based on consensus. 
Manual searches from reference lists of included studies were performed to identify additional 
trials. Eligibility was not restricted by language of publication or by trial design. Only published data 
from trials were included in the meta-analysis. Methodological quality and risk of bias for each trial 
were evaluated using the Cochrane Collaboration tool for assessing risk of bias (18). Publication bias 
was assessed by visually examining funnel plots for asymmetry. The systematic review was reported 
according to PRISMA (Preferred Reporting Items for Systematic Reviews) requirements. 
 
Meta-analysis sensitivity analyses 
For the meta-analysis, sensitivity analysis was conducted using falls in FEV1 of ≥15% because smaller 
falls in FEV1 may still be clinically significant. Missing standard deviations were calculated using 
individual patient data were available and from p-values using the method described by Elbourne et 
al. (19). For remaining missing values, the median p-value was imputed and sensitivity analyses 
performed using the minimum and maximum p-values to ensure conclusions remained consistent. 
All changes in FEV1 were calculated relative to baseline levels. 
 
 
 
SYSTEMATIC REVIEW AND META-ANALYSIS SUPPLEMENTARY RESULTS 
 
Supplementary figure 1: PRISMA flow diagram for the systematic review study selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Records identified through 
database searching  
(n = 198) 
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Full-text articles excluded  
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Ineligible exposure = 3 
Not asthmatic = 2 
No useable outcome = 1 
Exposure >1week = 2 
Not a clinical trial = 1 
Reported twice = 1 
No placebo = 1 
  
 
Supplementary table 4. Characteristics of included studies for the systematic review and meta-
analysis. 
 
*Selective beta-blocker. Only data from patients with asthma extracted from eligible studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study (reference) Number of 
asthmatic 
patients 
Trial 
randomized 
Trial 
blinded 
Ocular beta-blocker (concentration) 
Bleckmann 198720 10 Yes Yes Betaxolol (0.5%)* 
Bohm 198721 15 Yes Yes Timolol (0.5%), Metipranolol (0.6%), Pindolol (1%) 
De Vos 198922 2 No Yes Betaxolol (0.5%)* 
Dunn 198623 8 No Yes Betaxolol (1%)* 
Hugues 198524 15 No No Timolol (0.25-0.5%) 
Hugues 198725 20 No No Carteolol (1-2%), Metipranolol (0.3-0.6%) 
Schoene 198426 9 Yes Yes Betaxolol (1%)* 
Schoene 199227 4 No Yes Betaxolol (0.5%)* 
Vonwil 198128 5 Yes Yes Timolol (0.5%) 
Supplementary figure 2: Fall in FEV1 of 20% or greater following acute beta-blocker eye drop 
exposure. 
 
a) Acute non-selective beta-blocker eye drops in people with no prior exposure 
 
 
b) Acute selective beta-blocker exposure in people with prior sensitivity to non-selective eye drops 
 
 
 
 
 
 
 
 
 
 
 
Risk of bias from included clinical trials 
No significant statistical heterogeneity was detected. Of the nine included studies, five were non-
randomised and two were unblinded at high risk of bias (supplementary figure 4). No funnel plot 
asymmetry was found to suggest publication bias.  
 
Supplementary figure 4. Cochrane collaboration tool for assessing risk of bias among included 
studies. 
 
 
 
